Adult Paget's disease of bone: a review

被引:48
|
作者
Tuck, Stephen Paul [1 ,2 ]
Layfield, Robert [3 ]
Walker, Julie [4 ]
Mekkayil, Babitha [2 ]
Francis, Roger [1 ]
机构
[1] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England
[2] James Cook Univ Hosp, Rheumatol, Middlesbrough, Cleveland, England
[3] Univ Nottingham, Sch Med, Sch Life Sci, Dept Biochem, Nottingham, England
[4] James Cook Univ Hosp, Dept Histopathol, Middlesbrough, Cleveland, England
关键词
Paget's disease of bone; pathogenesis; management; complications; ZOLEDRONIC ACID; HEARING-LOSS; BIOCHEMICAL MARKERS; TURNOVER MARKERS; SINGLE INFUSION; RISEDRONATE; PATHOGENESIS; PAMIDRONATE; MANAGEMENT; MUTATIONS;
D O I
10.1093/rheumatology/kew430
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adult PD of bone is the second commonest metabolic bone condition after osteoporosis. The condition is characterized by increased bone cell activity, with bone-resorbing osteoclasts often larger and containing more nuclei than normal, and osteoblasts producing increased amounts of disorganized bone. This leads to expanded bone of poor quality possessing both sclerotic and lytic areas. PD of bone has a strong genetic element, with a family history being noted in 10-20% of cases. A number of genetic defects have been found to be associated with the condition. The most common disease-associated variants identified affect the SQSTM1 gene, providing insights into disease aetiology, with the clinical value of knowledge of SQSTM1 mutation status currently under active investigation. The diagnosis may be suggested by an isolated raised total ALP without other identifiable causes. This can be confirmed on plain X-rays and the extent determined by isotope bone scan. The mainstays of treatment are the bisphosphonates, especially i.v. zoledronate, which results in long-term suppression of bone turnover. ALP is the usual means of monitoring the condition, although more specific bone turnover markers can be helpful, especially in coincident liver disease. Patients should be followed up to monitor for biochemical relapse or development of complications, which may require medical or surgical intervention.
引用
收藏
页码:2050 / 2059
页数:10
相关论文
共 50 条
  • [41] Paget's Disease of Bone: A Disease of the Osteoclast
    Reddy S.V.
    Kurihara N.
    Menaa C.
    Roodman G.D.
    Reviews in Endocrine and Metabolic Disorders, 2001, 2 (2) : 195 - 201
  • [42] Diagnosis and treatment of Paget's disease of bone: a mini-review
    Ferraz-de-Souza, Bruno
    Silveira Correa, Pedro Henrique
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2013, 57 (08) : 577 - 582
  • [43] Paget's disease of the bone - Reply
    Zargar, AH
    Laway, BA
    Masoodi, SR
    Wani, AI
    Bashir, MI
    Tramboo, NA
    Khan, FA
    SAUDI MEDICAL JOURNAL, 2000, 21 (04) : 404 - 405
  • [44] Osteocytes and Paget's Disease of Bone
    Tenshin, Hirofumi
    Delgado-Calle, Jesus
    Windle, Jolene J.
    Roodman, G. David
    Chirgwin, John M.
    Kurihara, Noriyoshi
    CURRENT OSTEOPOROSIS REPORTS, 2024, 22 (02) : 266 - 272
  • [45] Paget's disease of bone or osteopetrosis?
    Rozin, Alexander
    Bar-Shalom, Rachel
    Ish-Shalom, Sofia
    CLINICAL RHEUMATOLOGY, 2006, 25 (04) : 544 - 547
  • [46] Is Paget’s disease of bone disappearing?
    T. Cundy
    Skeletal Radiology, 2006, 35 : 350 - 351
  • [47] Genetics of Paget’s Disease of Bone
    Stuart H. Ralston
    Omar M. E. Albagha
    Current Osteoporosis Reports, 2014, 12 : 263 - 271
  • [48] Genetics of Paget's disease of bone
    Daroszewska, A
    Ralston, SH
    CLINICAL SCIENCE, 2005, 109 (03) : 257 - 263
  • [49] IS PAGET'S BONE DISEASE IN RETIREMENT?
    Sanchez, Ariel
    REVISTA MEDICA DE ROSARIO, 2020, 86 (02): : 98 - 99
  • [50] Editorial: Paget’s disease of bone
    Peter Pietschmann
    Wiener Medizinische Wochenschrift, 2017, 167 (1-2) : 1 - 1